A Selective Estrogen Receptor Modulator Designed for the Treatment of Uterine Leiomyoma with Unique Tissue Specificity for Uterus and Ovaries in Rats
journal contributionposted on 03.11.2005 by Conrad W. Hummel, Andrew G. Geiser, Henry U. Bryant, Ilene R. Cohen, Robert D. Dally, Kin Chiu Fong, Scott A. Frank, Ronald Hinklin, Scott A. Jones, George Lewis, Denis J. McCann, Daniel G. Rudmann, Timothy A. Shepherd, Hongqi Tian, Owen B. Wallace, Minmin Wang, Yong Wang, Jeffrey A. Dodge
Any type of content formally published in an academic journal, usually following a peer-review process.
The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described. 16 (LY2066948−HCl) binds with high affinity to estrogen receptors α and β (ERα and ERβ, respectively) and is a potent uterine antagonist with minimal effects on the ovaries as determined by serum biomarkers and histologic evaluation.